Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001558370-25-005689
Filing Date
2025-04-28
Accepted
2025-04-28 16:30:18
Documents
18
Period of Report
2025-06-10

Document Format Files

Seq Description Document Type Size
1 DEF 14A xlo-20250610xdef14a.htm   iXBRL DEF 14A 839592
2 GRAPHIC xlo-20250610xdef14a_a003.jpg GRAPHIC 9237
3 GRAPHIC xlo-20250610xdef14a_a004.jpg GRAPHIC 1490
4 GRAPHIC xlo-20250610xdef14a_bg001.jpg GRAPHIC 123093
5 GRAPHIC xlo-20250610xdef14a_bg002.jpg GRAPHIC 93788
  Complete submission text file 0001558370-25-005689.txt   1766139

Data Files

Seq Description Document Type Size
6 EX-101.SCH xlo-20250610.xsd EX-101.SCH 3666
7 EX-101.LAB xlo-20250610_lab.xml EX-101.LAB 3686
8 EX-101.PRE xlo-20250610_pre.xml EX-101.PRE 3523
20 EXTRACTED XBRL INSTANCE DOCUMENT xlo-20250610xdef14a_htm.xml XML 48525
Mailing Address 828 WINTER STREET WALTHAM MA 02451
Business Address 828 WINTER STREET WALTHAM MA 02451 617-833-1027
Xilio Therapeutics, Inc. (Filer) CIK: 0001840233 (see all company filings)

EIN.: 851623397 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-40925 | Film No.: 25880841
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)